Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Philipp Harter
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
214 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Graz, Austria
- Research Site
Innsbruck, Austria
- Research Site
Linz, Austria
- Research Site
Vienna, Austria
- Research Site
Aalst, Belgium
- Research Site
Leuven, Belgium
- Research Site
Namur, Belgium
- Research Site
Ostend, Belgium
- Research Site
Sint-Niklaas, Belgium
- Research Site
Barretos, Brazil
- Research Site
Florianópolis, Brazil
- Research Site
Fortaleza, Brazil
- Research Site
Londrina, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Rio de Janeiro, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Burgas, Bulgaria
- Research Site
Plovdiv, Bulgaria
- Research Site
Sofia, Bulgaria
- Research Site
Varna, Bulgaria
- Research Site
Calgary, Alberta, Canada
- Research Site
Barrie, Ontario, Canada
- Research Site
Greater Sudbury, Ontario, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Québec, Quebec, Canada
- Research Site
Rimouski, Quebec, Canada
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Bengbu, China
- Research Site
Changchun, China
- Research Site
Changsha, China
- Research Site
Changsha, China
- Research Site
Chengdu, China
- Research Site
Chongqing, China
- Research Site
Dalian, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Jan 2019
- Primary completion
- 17 Mar 2025
- Completion
- 23 Dec 2026
- Last update posted
- 7 Jul 2026
- Registered enrollment
- 1,407
- Registry id
- NCT03737643
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.